<DOC>
	<DOC>NCT03062956</DOC>
	<brief_summary>Up to 56 healthy volunteers will be given a single dose of MYK-491 or placebo and be monitored for safety and tolerability over a 7 day period.</brief_summary>
	<brief_title>A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491</brief_title>
	<detailed_description>Up to 56 healthy volunteers will be given a single dose of MYK-491 or placebo and be monitored for safety and tolerability over a 7 day period. After the 28 day screening period, the eligible subject will be admitted to the clinical site and will receive a single dose of study drug or placebo. Subjects will be confined to the clinical site for five days (Day -1 to Day 4) and will return to the clinic on Day 7 for a safety follow-up.</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy, Dilated</mesh_term>
	<criteria>Weight between 60 and 90 kg inclusive Resting heart rate of &lt; 80 beats per minute Documented LVEF greater than or equal to 55% during Screening Normal electrocardiogram (ECG) at Screening Normal acoustic windows on transthoracic echocardiograms at Screening All safety laboratory parameters within normal limits at Screening History or evidence of another clinically significant disorder, in the opinion of the investigator. Active infection History of coronary artery disease History of malignancy with the exception of in situ cervical cancer more than 5 years prior to Screening or surgicallyexcised nonmelanomatous skin cancers more than 2 years prior to Screening Positive serology tests at screening Current use of tobacco or nicotinecontaining products exceeding 10 per day.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>